CELH is criminally undervalued after a great Q1 report. $20k weekly yolo
Title says it all. They just posted 200m of quarterly EBITDA and now trading at 10x 2026 EBITDA.
Source material behind every call on the tape.
Title says it all. They just posted 200m of quarterly EBITDA and now trading at 10x 2026 EBITDA.
**TL;DR** $NXE just got the FINAL permit for the only large-scale uranium project in the Western world. Hyperscalers are panic-buying nuclear because GPUs need power and renewables can't run at 3am. Russia, Niger, and Kazakhstan supply most of the world's …
28yo here. Been investing for 5 years, but over the last year I’ve taken it much more seriously, mainly swing trading alongside some longer-term holds. What’s frustrating is that around 70% of the stocks I’ve added to my watchlist have …
28yo here. Been investing for 5 years, but over the last year I’ve taken it much more seriously, mainly swing trading alongside some longer-term holds. What’s frustrating is that around 70% of the stocks I’ve added to my watchlist have …
28yo here. Been investing for 5 years, but over the last year I’ve taken it much more seriously — mainly swing trading alongside some longer-term holds. What’s frustrating is that around 70% of the stocks I’ve added to my watchlist …
I’m just college student who has spent more time reading biotech clinical trial protocols than studying for my exams. I’m $30k+ deep into this. I am a regard, and this is a casino. And yeah this is written by ai …
OpenAI just closed a $122B funding round at an $852B valuation and now reports are saying firms like Goldman Sachs, JPMorgan, and Morgan Stanley are already discussing the IPO side of things. They’re apparently targeting a $1T valuation eventually while …
Reports Q1 2026 results Wednesday May 14th after close. Stock sits at $13.48right on a critical demand zone ($13–13.50) after a clear downtrend with multiple bearish CHoCH signals on the daily. Consensus expects EPS of $0.20 and revenue of $5.10B. …
Hey guys, sharing an update on the **$17million settlement involving $RVNC**. As [claims are being accepted,](https://11th.com/cases/revance-investor-settlement) here’s a quick overview: Revance Therapeutics was accused of its Teoxane dispute, delayed Crown tender offer, and related stock-price declines. Following these disclosures, the …
I’m in a covered-call mess and want to hear how experienced CC traders would manage it. I own 609 shares of NVDA. Current short calls expiring 05/13/26: \- Short 4x NVDA $172.50C \- Short 2x NVDA $185C For context, I …